About NIMGenetics
NIMGenetics is a company based in Madrid (Spain) founded in 2007 was acquired by Veritas Genetics in January 2025. NIMGenetics has raised $7.63 million across 2 funding rounds from investors including Veritas Genetics, European Union and Apposite Capital. NIMGenetics has completed 1 acquisition, including Gene Predictis. NIMGenetics offers products and services including TrisoNIM, GenoNIM, ExoNIM, and NIMSeq. NIMGenetics operates in a competitive market with competitors including MedGenome, Foundation Medicine, Personalis, Veritas Genetics and Burning Rock, among others.
- Headquarter Madrid, Spain
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7.63 M (USD)
in 2 rounds
-
Latest Funding Round
$7.63 M (USD), Series A
May 10, 2017
-
Investors
Veritas Genetics
& 2 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
Veritas Genetics
(Jan 20, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NIMGenetics
NIMGenetics offers a comprehensive portfolio of products and services, including TrisoNIM, GenoNIM, ExoNIM, and NIMSeq.
Detects aneuploidies and deletions for prenatal diagnostics.
Enables genomic analysis for various medical applications.
Provides complete exome analysis for genetic disorders.
Offers sequencing services for prenatal and postnatal testing.
People of NIMGenetics
Unlock access to complete
Funding Insights of NIMGenetics
NIMGenetics has successfully raised a total of $7.63M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $7.63 million completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NIMGenetics
NIMGenetics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Veritas Genetics, European Union and Apposite Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare impact investments are managed by Apposite Capital.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Genetic testing products for health risks and traits are offered.
|
Locked | Locked | Locked |
Investor details for NIMGenetics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NIMGenetics
NIMGenetics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Gene Predictis.
Investment portfolio details for NIMGenetics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Genomic tests are developed for personalized medicine risks.
|
Locked | Locked | 0 | Locked |
Complete acquisition details for NIMGenetics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - NIMGenetics
Detailed financials for NIMGenetics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nimgenetics Comparisons
Peer comparison for NIMGenetics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NIMGenetics
NIMGenetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MedGenome, Foundation Medicine, Personalis, Veritas Genetics and Burning Rock, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
DNA sequencing, bioinformatics, and multiomics services are provided.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Genetic testing products for health risks and traits are offered.
|
|
| Locked | Locked | Locked |
Personalized cancer diagnostics are developed using genomic big data analysis.
|
|
| Locked | Locked | Locked |
Drug and companion diagnostics for multi-drug resistant cancers are developed.
|
Detailed competitors of NIMGenetics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nimgenetics
Complete news archive for NIMGenetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NIMGenetics
NIMGenetics was founded in 2007 and raised its 1st funding round 10 years after it was founded.
NIMGenetics is headquartered in Madrid, Spain. It is registered at Madrid, Madrid, Spain.
NIMGenetics is a funded company, having raised a total of $7.63M across 2 funding rounds to date.
Diagnostic solutions based on microarray and next-generation sequencing technologies. The company develops products for both the clinical and research markets. It has three product families for clinical diagnostics TRISONIM, a non-invasive prenatal test for the most commonly diagnosed fetal abnormalities KARYONIM, a range of products for invasive fetal and neonatal testing for chromosomal abnormalities and ONCONIM, which contains one test for BRCA testing, and two gene panels for enabling precision medicine in cancer patients. In addition, NIMGenetics has NIMFISH which is a range of customized FISH probes and EXONIM for whole exome sequencing. NIMGenetics is certified by Life Technologies (now ThermoFisher) for exome sequencing.
NIMGenetics's top competitors include Foundation Medicine, MedGenome and Personalis.
NIMGenetics offers TrisoNIM, GenoNIM, ExoNIM, and NIMSeq.
NIMGenetics has made 1 acquisition, including Gene Predictis.
NIMGenetics has 3 investors. Key investors include Veritas Genetics, European Union, and Apposite Capital.